All In MedTech

Device Trial Radar · NCT05675345

Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure

Physiological Effects of Continuous Negative External Pressure for Acute Hypoxemic Respiratory Failure: A Pilot Crossover Trial

Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Feb 28, 2024

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
NYU Langone HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 9, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate if wearing a non-invasive breathing support device over the chest/abdomen improves markers of breathing in patients with lung injury requiring high-flow oxygen. The breathing support device consists of a plastic shell that sits over the chest and abdomen and connects to a vacuum that helps the chest expand with breathing. This breathing support is known as continuous negative external pressure (CNEP). Study findings will help determine if this breathing support device might be useful for patients with acute hypoxemic respiratory failure (AHRF).

Conditions

  • Acute Hypoxemic Respiratory Failure

Interventions

  • HFNC onlyDevice

    HFNC for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

  • HFNC + CNEP10Device

    HFNC with CNEP of 10 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

  • HFNC + CNEP20Device

    HFNC with CNEP of 20 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

  • HFNC + CNEP30Device

    HFNC with CNEP of 30 cmH2O for 45 minutes, with FiO2 titrated to SpO2 of 90-97%

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in SpO2/FiO2Time frame: At the end of each treatment period, up to 45 minutes

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • NYU Langone Health - Brooklyn Hospital

    Brooklyn, New York · Recruiting

  • Bellevue Hospital

    New York, New York · Recruiting

  • NYU Langone Health - NYU Tisch-Kimmel Hospital

    New York, New York · Recruiting

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.